About this item:

231 Views | 346 Downloads

Author Notes:

Corresponding author: Danni Li. Tel.: 612-626-0299; Fax: 612-625-1121. E-mail address: dannili@umn.edu.

We thank the staff and participants of the ARIC Study for their important contributions.

Drs. Danni Li and Alvaro Alonso had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Dr. Knopman previously served as Deputy Editor for Neurology; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals, Biogen and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH. Dr. Gottesman serves as Associate Editor for Neurology and receives research support from the NIH. Dr. Boerwinkle receives research support from NIH. Drs. Li, Sharrett, Mosley, Coresh, Wruck, and Alonso report no disclosures; Mr. Misialek reports no disclosures.


Research Funding:

The Atherosclerosis Risk in Community (ARIC) Study is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN2682011000010C, HHSN2682011000011C, and HHSN2682011000012C).

Neurocognitive data are collected by the support of the National Heart, Lung, and Blood Institute U01 HL096812, HL096814, HL096899, HL096902, and HL096917 with previous brain MRI examinations funded by R01-HL70825.


  • AD
  • ARIC
  • Alzheimer's disease
  • Dementia
  • MCI
  • Metabolites
  • Metabolomics
  • Mild cognitive impairment
  • Phospholipids
  • Plasma

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study


Journal Title:

Alzheimer's and Dementia


Volume 6


, Pages 1-10

Type of Work:

Article | Final Publisher PDF


Introduction: The objective of this study was to investigate whether 10 phospholipids/metabolites previously identified as prospectively predictive of mild cognitive impairment (MCI) or dementia in whites would also be predictive in a mostly African-American cohort. Methods: We repeatedly measured 188 phospholipids/metabolites in plasma samples of 221 participants of the Atherosclerosis Risk in Communities study, 97% African American, who were followed between 2004–2006 and 2011–2013. Results: After a mean follow-up of 7.3 years, 77 were classified as having MCI and 18 as having dementia. Our study failed to replicate previous findings in this mostly African American cohort, in that the 10 phospholipids/metabolites only achieved a C statistic/AUC of 0.609 in predicting development of MCI or dementia (compared to 0.96) and 0.607 in distinguishing normal from MCI or dementia at the follow-up visit. Conclusion: A panel of 10 phospholipids/metabolites previously associated with incident dementia was not predictive of MCI or dementia in an independent cohort.

Copyright information:

© 2016 The Authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote